Premium
OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study
Author(s) -
Domínguez C.,
PozoRosich P.,
TorresFerrús M.,
HernándezBeltrán N.,
JuradoCobo C.,
GonzálezOria C.,
Santos S.,
Monzón M. J.,
Latorre G.,
Álvaro L. C.,
Gago A.,
Gallego M.,
Medrano V.,
Huerta M.,
GarcíaAlhama J.,
Belvís R.,
Leira Y.,
Leira R.
Publication year - 2018
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/ene.13523
Subject(s) - medicine , chronic migraine , migraine , headaches , odds ratio , prospective cohort study , adverse effect , confidence interval , pediatrics , physical therapy , surgery
Background and purpose OnabotulinumtoxinA is a treatment specifically approved for the prophylaxis of chronic migraine in adults. The aim of this study was to assess the effectiveness of OnabotulinumtoxinA in chronic migraine after 1 year of treatment in a real‐life setting and to identify clinical predictors of outcome. Methods We designed a prospective multicentre study performed in 13 hospitals in Spain. Patients underwent a complete medical history and examination. They were treated with OnabotulinumtoxinA every 12 weeks for 1 year. Data about outcome, adverse events, abortive medication use, emergency room use and disability were collected at 3 and 12 months. Results A total of 725 subjects completed the study. At 12 months, 79.3% showed >50% reduction in number of headaches per month and 94.9% reported no adverse events. Unilaterality of pain, fewer days of disability per month and milder headache at baseline were correlated with good outcome. Duration of disease <12 months increased the chances of response to treatment with OnabotulinumtoxinA (odds ratio, 1.470; 95% confidence interval, 1.123–2.174; P = 0.045). Conclusions This study confirmed the effectiveness of treatment with OnabotulinumtoxinA after 1 year of treatment. The chances of a good outcome may be increased by starting treatment in the first 12 months after chronic migraine diagnosis.